Patients with pathogenic variants in SLC35A2 (SLC35A2-CDG) are characterized by neurological manifestations, including growth failure, structural brain abnormalities, developmental delay, and epilepsy, as well as other clinical features such as muscle hypotonia, skeletal abnormalities, distinctive facial appearances, and liver dysfunction [72,73]. This evidence concerns the gene SLC35A2 and epilepsy.